Prosigna Breast Cancer Prognostic Gene Signature Assay
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene expression assay
diagnostic assay |
| gptkbp:analyzes |
RNA from breast tumor tissue
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:basedOn |
PAM50 gene signature
|
| gptkbp:CEMarked |
yes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prosigna Breast Cancer Prognostic Gene Signature Assay
|
| gptkbp:manufacturer |
gptkb:NanoString_Technologies
|
| gptkbp:measures |
risk of recurrence
|
| gptkbp:medicalUse |
adjuvant treatment decision-making
|
| gptkbp:platform |
nCounter Analysis System
|
| gptkbp:predicts |
10-year risk of distant recurrence
|
| gptkbp:provides |
risk score
intrinsic subtype classification |
| gptkbp:recognizedBy |
Basal-like subtype
HER2-enriched subtype Luminal A subtype Luminal B subtype |
| gptkbp:type |
formalin-fixed, paraffin-embedded tissue
|
| gptkbp:usedFor |
breast cancer prognosis
|
| gptkbp:usedIn |
postmenopausal women with early-stage breast cancer
|
| gptkbp:bfsParent |
gptkb:Veracyte
|
| gptkbp:bfsLayer |
7
|